News

Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy
Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the ...
pharmaphorum5d
ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC
Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...
MedPage Today6d
First-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast Cancer
CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...